Skip to Main Content
Contribute Try STAT+ Today

Back in 2016, a 6-year-old named Mila was diagnosed with Batten disease, a progressive and incurable genetic syndrome that would brutally strip away her sight and her ability to walk, and would cause dozens of seizures each day. The condition is fatal.

But her parents, Julia Vitarello and Alek Makovec, refused to lose hope. They contacted Dr. Tim Yu, a neurologist at Boston Children’s Hospital, who discovered the precise genetic mutation that caused her disease — and was able to devise an experimental treatment designed exclusively for Mila. His work is one of the first examples of therapies created for the benefit of a single patient — an “N of 1” study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.